Compare Ginkgo Bioworks Holdings Inc (DNA) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Banco Santander SA — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.78 (market cap $763.64M), while Banco Santander SA trades at $13.56 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 252.6× Ginkgo Bioworks Holdings Inc's market cap, and Banco Santander SA pays a 2.06% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Banco Santander SA for 55 Days on average.
| DNA | SAN | |
|---|---|---|
Market Cap | $763.64M | $192.86B |
Volume | 3,204,177 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $15.83 | $15.05 |
52-Week Low | $5.48 | $9.65 |
Typical Hold Time | 7 Days | 55 Days |
Enterprise Value | $865.59M | $360.86B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
Banco Santander (SAN) trades at $13.66, down 2.5% today, with technical indicators showing bearish momentum. The company reported strong fundamentals with Q2 2026 net income of $14.10 billion and a 26.25% net margin, though cash flow trends show recent operational challenges. Recent developments include the completion of the Webster Financial acquisition, expanding Santander's U.S. presence and diversification.
Outlook remains mixed with analyst consensus at 'Moderate Buy' (64% buy ratings) but technical weakness. Key opportunities include record profitability and strategic acquisitions, while risks involve declining cash flows and high debt levels. The stock's valuation appears reasonable with P/E of 13.55 and P/B of 1.58.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
